Strategic Acquisition Resolution Bioscience is now part of Exact Sciences, indicating potential access to larger enterprise customers, expanded distribution channels, and cross-sell opportunities for diagnostic panels and companion tests.

Clinical Collaboration Past partnerships with Mirati Therapeutics and LabCorp suggest a strong model for co-development and distribution; leverage these relationships to pursue new companion diagnostics, liquid biopsy workflows, and payer-backed tests.

Companion Diagnostics With over 50 focused panels in development, there is clear demand for FGx-enabled tests linked to targeted therapies; opportunities exist to position additional panels for late-stage trials or approved therapies seeking IDE/HTA support.

Liquid Biopsy Focus Specialization in noninvasive cfDNA analytics aligns with rising adoption of liquid biopsy in oncology; target hospitals, academic centers, and community sites expanding liquid biopsy programs and reimbursement.

SMB to Enterprise Company size and revenue profile indicate potential to engage at both strategic enterprise levels for large-scale deployments and mid-market opportunities for pilot programs with Exact Sciences’ installed base.